The effectiveness of influenza vectors expressing the protective mycobacterial antigen ESAT-6 in the complex therapy of generalized tuberculosis in mice

• Published in: Problemy tuberkuleza i bolezneĭ legkikh no. 12; p. 30
• Main Authors: Zabolotnykh, N V, Vinogradova, T I, Stukova, M A, Vasil'eva, S N, Vitovskaia, M L, Egorov, A Iu
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2008
• Subjects: Animals; Antigens, Bacterial; Bacterial Proteins; Data Interpretation, Statistical; Disease Models, Animal; Genetic Vectors; Immunization - methods; Lung - pathology; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis - growth & development; Mycobacterium tuberculosis - immunology; Orthomyxoviridae; Phagocytosis; Tuberculosis - immunology; Tuberculosis - pathology; Tuberculosis - prevention & control; Tuberculosis - therapy; Tuberculosis Vaccines
• ISSN: 1728-2993

The use of Flu/ESAT-6 in chemotherapy for experimental tuberculosis has been found to cause a significant improvement of its results, which appears as the higher clearance of lung tissue from mycobacteria, the reduced extent of specific inflammation foci, and the altered cell composition of granulomas with mainly epithelioid to mainly lymphoid one. Flu/ESAT-6 of Tx-1 immunity (spontaneous and phytohemagglutinin-induced proliferation of splenocytes, spontaneous production of gamma-IFN) and ESAT-6-specific stimulation of a cell immune response (the proliferative activity of splenic lymphocytes and the production of IL-2 in response to recESAT-6) is shown to activate. The influenza vector A/PR8/NS1-125 that contains no ESAT-6 insert shows immunoadjuvant properties, which is likely to cause some reduction in the severity of tuberculosis in the control group of the vaccine.